Biotech Winners And Losers Out Of ASH
A slew of biotech companies studying blood disease treatments presented data this past weekend at the annual American Society of Hematology (ASH) meeting – and,…
Wall Street
Biggest Biotech Bargains
“Although the vast majority of biotech stocks are losing money, a handful of these profitable drug developers are valued at levels that make them absolute…
Stocks To Watch In March (Besides All Of Them)
“The final week of February swallowed up all of Wall Street’s year-to-date gains – and then some. Given this level of volatility, one could argue…
“The Most Blatant Warning” For The Stock Market That’s Being Overlooked
From the yield curve inversion (which has preceded every recession since the end of World War II) to the very high – and rising –…
3 Stocks Primed For Real-Deal, Long-Term Growth
When it comes to growth, there’s blink-and-you’ll-miss-it growth and then there’s serious, real-deal, long-term growth. Today’s article focuses on the latter, highlighting three stocks “primed…
“Solid Alpha Potential”: 5 Stocks Under $10 For Aggressive Traders
An “off-the-radar” financial intermediary with a massive 10.21% dividend, a potential acquisition target in the gaming industry and an oil services play that’s a top…
The “Perfect 10 Portfolio” For The Coming Year
The author of today’s article has compiled 16 “Perfect 10 Portfolios” (consisting of stocks that have a price/earnings ratio of 10) since 2000 – and…
From Most Bearish To Super Bullish: Top Wall Street Strategists’ S&P 500 Forecasts For 2019
“As investors, we must properly forecast the future AND put our money where our forecasts are,” acknowledges the author of today’s article. He proceeds to…
What’s Worth Grabbing In “GARP Land”?
The author of today’s article considers stocks selling for 15 times earnings per share or less to be value territory, stocks selling for 20 times…
These 3 Stocks With Attractive Dividends Are Now Available At A Discount
“Right now, after a nice bout of selling, you can identify a few stocks trading below their book value — which pay dividends and have…